|Bid||0.00 x 800|
|Ask||0.00 x 1300|
|Day's range||202.00 - 206.43|
|52-week range||176.36 - 242.99|
|Beta (5Y monthly)||0.60|
|PE ratio (TTM)||24.44|
|Earnings date||31 Jan 2022 - 04 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||255.01|
Buying innovators and disruptors at a discount is a smart way to set yourself up for long-term success.
Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) spiked recently in response to good news for an experimental new drug. Successful results from a clinical trial with a drug that isn't part of the company's successful cystic fibrosis franchise are generating a lot of stock market buzz for Vertex Pharmaceuticals again. On Dec. 1, 2021, Vertex Pharmaceuticals' stock jumped after the company posted results from a human proof-of-concept study with VX-147.
The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma